Evidence map›Paper›PMID 38036879›Full record

ArticleAdvances in experimental medicine and biology2024

The Cholesterol-5,6-Epoxide Hydrolase: A Metabolic Checkpoint in Several Diseases.

Philippe de Medina, Silia Ayadi, Khadijetou Diallo, Julio Buñay, Laly Pucheu, Regis Soulès, Michel Record, Severine Brillouet, Lavinia Vija, Frederic Courbon and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in experimental medicine and biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
13.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Philippe de Medina *Cancer Research Center of Toulouse (CRCT), Inserm, CNRS, University of Toulouse, Team INOV: "Cholesterol Metabolism and Therapeutic Innovations", Toulouse, France.
Silia AyadiCancer Research Center of Toulouse (CRCT), Inserm, CNRS, University of Toulouse, Team INOV: "Cholesterol Metabolism and Therapeutic Innovations", Toulouse, France.
Khadijetou DialloCancer Research Center of Toulouse (CRCT), Inserm, CNRS, University of Toulouse, Team INOV: "Cholesterol Metabolism and Therapeutic Innovations", Toulouse, France.
Julio BuñayCancer Research Center of Toulouse (CRCT), Inserm, CNRS, University of Toulouse, Team INOV: "Cholesterol Metabolism and Therapeutic Innovations", Toulouse, France.
Laly PucheuCancer Research Center of Toulouse (CRCT), Inserm, CNRS, University of Toulouse, Team INOV: "Cholesterol Metabolism and Therapeutic Innovations", Toulouse, France.
Regis SoulèsCancer Research Center of Toulouse (CRCT), Inserm, CNRS, University of Toulouse, Team INOV: "Cholesterol Metabolism and Therapeutic Innovations", Toulouse, France.
Michel RecordCancer Research Center of Toulouse (CRCT), Inserm, CNRS, University of Toulouse, Team INOV: "Cholesterol Metabolism and Therapeutic Innovations", Toulouse, France.
Severine BrillouetCancer Research Center of Toulouse (CRCT), Inserm, CNRS, University of Toulouse, Team INOV: "Cholesterol Metabolism and Therapeutic Innovations", Toulouse, France.
Lavinia VijaCancer Research Center of Toulouse (CRCT), Inserm, CNRS, University of Toulouse, Team INOV: "Cholesterol Metabolism and Therapeutic Innovations", Toulouse, France.
Frederic CourbonCancer Research Center of Toulouse (CRCT), Inserm, CNRS, University of Toulouse, Team INOV: "Cholesterol Metabolism and Therapeutic Innovations", Toulouse, France.
Sandrine Silvente-Poirot *Cancer Research Center of Toulouse (CRCT), Inserm, CNRS, University of Toulouse, Team INOV: "Cholesterol Metabolism and Therapeutic Innovations", Toulouse, France.
Marc Poirot *Cancer Research Center of Toulouse (CRCT), Inserm, CNRS, University of Toulouse, Team INOV: "Cholesterol Metabolism and Therapeutic Innovations", Toulouse, France. marc.poirot@inserm.fr.
La Ligue Contre le Cancer · FRInserm · FRCentre National de la Recherche Scientifique · FRFrench Clinical Research Infrastructure Network · FRCentre de Recherche en Cancérologie de Toulouse · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cholesterol-5,6-epoxides (5,6-ECs) are oxysterols (OS) that have been linked to several pathologies including cancers and neurodegenerative diseases. 5,6-ECs can be produced from cholesterol by several mechanisms including reactive oxygen species, lipoperoxidation, and cytochrome P450 enzymes. 5,6-ECs exist as two different diastereoisomers: 5,6α-EC and 5,6β-EC with different metabolic fates. They can be produced as a mixture or as single products of epoxidation. The epoxide ring of 5,6α-EC and 5,6β-EC is very stable and 5,6-ECs are prone to hydration by the cholesterol-5,6-epoxide hydrolase (ChEH) to give cholestane-3β,5α,6β-triol, which can be further oxidized into oncosterone. 5,6α-EC is prone to chemical and enzymatic conjugation reactions leading to bioactive compounds such as dendrogenins, highlighting the existence of a new metabolic branch on the cholesterol pathway centered on 5,6α-EC. We will summarize in this chapter current knowledge on this pathway which is controlled by the ChEH.

Indexed as

Epoxide HydrolasesNeoplasmsCholesterolEpoxy CompoundsHumansReactive Oxygen SpeciesCholesterolEpoxide HydrolasesEpoxy CompoundsReactive Oxygen SpeciesAutophagyCancerCell differentiationCholesterolDendrogeninsExosomesOncosteroneOxysterolSterols

Identifiers

PMID38036879
OpenAlexW4389209834

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.